Opus Genetics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Opus Genetics, Inc. (IRD) reported Revenue from Contract with Customer, Including Assessed Tax of $3.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2020-02-21
- Opus Genetics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-12-31 was $0.00.
- Opus Genetics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $0.00.
- Opus Genetics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-06-30 was $0.00.
- Opus Genetics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-03-31 was $3.00M.
- Opus Genetics, Inc. revenue from contract with customer, including assessed tax for fiscal 2019 was $3.00M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $0.00 derived: sum of 2 quarters · filed 2020-02-21 | $0.00 derived: sum of 3 quarters · filed 2020-02-21 | $3.00M 10-K · filed 2020-02-21 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $3.00M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $3.00M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $3.00M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |